Indian pharma major Wockhardt Wednesday announced the launch of its antibiotic tablets Cefprozil in the US after receiving approval from the US Food and Drug Administration (US FDA).
Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections.
"Several of our products have seen a dramatic increase in the market share in the US over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million," Wockhardt chairman Habil Khorakiwala said in a statement.
The Cefprozil tablets, developed in-house, are manufactured at Wockhardt's US FDA certified formulation plant at Waluj in Maharashtra.
The $650 million firm has a market capitalisation of over $1 billion and has major presence in the markets of the US, Britain, Ireland, Germany and France. It employs over 7,000 professionals both in India and abroad.